Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks
without a dose matrix, they cannot distinguish additivity from synergy
Monday Poster Session Category: Small Intestine P4045 - Comparative Risk of Small Intestinal Bacterial Overgrowth (SIBO) Among Patients Using GLP-1 Receptor Agonists: A Real-World Analysis Using TriNetX Monday, October 27, 2025 10:30 AM - 4:00 PM PDT Location: Exhibit Hall Has Audio Presenting Author(s) Lina AlQirem, MD 1 , Suria Devarapalli, DO 1 , Adalberto Guzman, MD 2 , Murad Qirem, MD 3 , Meer A
He is a consultant/advisory board member for Boehringer Ingelheim, Currax Pharmaceuticals, Lilly, Altimmune, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novo Nordisk, Pfizer, Veru Pharmaceuticals, Zealand Pharmaceuticals and Amgen
While GLP-1s are generally well tolerated and offer numerous health benefits from weight loss and better glucose control to a lower risk of cardiovascular disease research suggests they could increase the risk of certain serious eye conditions
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
